Sodium channel blockers - Pipeline Insight, 2024

This “Sodium Channel Blockers - Pipeline Insight, 2024” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Sodium Channel Blockers pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Sodium Channel Blockers Understanding

Sodium Channel Blockers: Overview

Sodium-channel blockers comprise the Class I antiarrhythmic compounds according to the Vaughan-Williams classification scheme. These drugs bind to and block the fast sodium channels that are responsible for the rapid depolarization (phase 0) of fast-response cardiac action potentials. This type of action potential is found in non-nodal, cardiomyocytes (e.g., atrial and ventricular myocytes; purkinje tissue). Because the slope of phase 0 depends on the activation of fast sodium-channels and the rapid entry of sodium ions into the cell (Figure: Na+ in), blocking these channels decreases the slope of phase 0, which also leads to a decrease in the amplitude of the action potential.

Sodium Channel Blockers cross the blood-brain barrier and act through multiple mechanisms. They inhibit the gamma-aminobutyric acid (GABA) system (primarily lidocaine), activate the sodium ouabain-sensitive current, stimulate 5-TH2C receptors, antagonize H1 receptors and block all noradrenaline activating effect. It is through these actions that adrenergic stimulation occurs. These medications in large doses are also pro-convulsant through the above mechanisms.

Medications that act by sodium channel blockade have a wide variety of clinical applications. Broadly they include Vaughn Williams Class 1 antiarrhythmics, local anesthetics, many medications used to treat neuropathic pain (including tricyclic antidepressants (TCAs)), anticonvulsants, and cocaine. Complications of sodium channel blocker toxicity include cardiogenic shock, hypotension, bradycardia or tachycardia, cardiovascular collapse, respiratory depression, encephalopathy, status epilepticus, and death.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Sodium Channel Blockers R&D. The therapies under development are focused on novel approaches for Sodium Channel Blockers.

Sodium Channel Blockers Emerging Drugs Chapters

This segment of the Sodium Channel Blockers report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Sodium Channel Blockers Emerging Drugs

Cenobamate: SK bio Pharmaceuticals Cenobamate was discovered and developed by SK Biopharmaceuticals and SK life science. It is approved for Partial epilepsies. SK Biopharmaceuticals also has an exclusive licensing agreement with Ono Pharmaceutical to develop and commercialize cenobamate inJapan.

It is currently in Phase III stage of development for Tonic-clonic epilepsy and is being developed by SK biopharmaceuticals.

BIIB095: Biogen BIIB095 is a voltage- and use- dependent sodium channel blocker. It is a centrally and peripherally acting smallmolecule.

It is currently in Phase I stage of development for Neuropathic pain and is being developed by Biogen.

Sodium Channel Blockers: Therapeutic Assessment

This segment of the report provides insights about the different Sodium Channel Blockers drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Sodium Channel Blockers

There are approx. 30+ key companies which are developing the Sodium Channel Blockers. The companies which have their Sodium Channel Blockers drug candidates in the most advanced stage, i.e. Phase III include, SK biopharmaceuticals.

Phases

This report covers around 30+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Sodium Channel Blockers pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Sodium Channel Blockers: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Sodium Channel Blockers therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sodium Channel Blockers drugs.

Sodium Channel Blockers Report Insights

• Sodium Channel Blockers Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Sodium Channel Blockers Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Sodium Channel Blockers drugs?
• How many Sodium Channel Blockers drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Sodium Channel Blockers?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Sodium Channel Blockers therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Sodium Channel Blockers and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Biogen
• Parion Sciences
• Alpha NaviPharma
• Vertex Pharmaceuticals
• SK biopharmaceuticals
• UCB Biopharma

Key Products

• BIIB095
• P-1037
• ANP-230
• VX-548

Research programme: NaV1.8 inhibitor pain therapeutics- Cenobamate

• Lacosamide

This product will be delivered within 2 business days.